206 related articles for article (PubMed ID: 36036988)
21. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
22. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Accuracy of CT for Evaluating Circumferential Resection Margin Status in Resectable or Borderline Resectable Pancreatic Head Cancer: A Prospective Study Using Axially Sliced Surgical Pathologic Correlation.
Park JH; Yoon YS; Lee S; Kim HY; Han HS; Lee JS; Chang W; Kim H; Na HY; Han S; Lee KH
Korean J Radiol; 2022 Mar; 23(3):322-332. PubMed ID: 35029083
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271
[TBL] [Abstract][Full Text] [Related]
25. Pre-Operative MDCT Staging Predicts Mesopancreatic Fat Infiltration-A Novel Marker for Neoadjuvant Treatment?
Safi SA; Haeberle L; Heuveldop S; Kroepil P; Fung S; Rehders A; Keitel V; Luedde T; Fuerst G; Esposito I; Ziayee F; Antoch G; Knoefel WT; Fluegen G
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503170
[No Abstract] [Full Text] [Related]
26. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
[TBL] [Abstract][Full Text] [Related]
27. Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery.
Lee B; Yoon YS; Kang M; Park Y; Lee E; Jo Y; Lee JS; Lee HW; Cho JY; Han HS
Ann Surg Oncol; 2023 Jun; 30(6):3444-3454. PubMed ID: 36695994
[TBL] [Abstract][Full Text] [Related]
28. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
Noda Y; Pisuchpen N; Mercaldo ND; Sekigami Y; Michelakos T; Parakh A; Wo JY; Qadan M; Ferrone C; Lillemoe KD; Ryan DP; Clark JW; Fernandez-Del Castillo C; Hong TS; Kambadakone AR
Eur Radiol; 2022 Apr; 32(4):2470-2480. PubMed ID: 34665317
[TBL] [Abstract][Full Text] [Related]
29. The impact of extent of pancreatic and venous resection on survival for patients with pancreatic cancer.
Serenari M; Ercolani G; Cucchetti A; Zanello M; Prosperi E; Fallani G; Masetti M; Lombardi R; Cescon M; Jovine E
Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):389-394. PubMed ID: 31230959
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival.
Belfiori G; Crippa S; Francesca A; Pagnanelli M; Tamburrino D; Gasparini G; Partelli S; Andreasi V; Rubini C; Zamboni G; Falconi M
Ann Surg Oncol; 2021 Dec; 28(13):8249-8260. PubMed ID: 34258720
[TBL] [Abstract][Full Text] [Related]
31. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
32. Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019.
Delpero JR; Sauvanet A
Front Oncol; 2020; 10():40. PubMed ID: 32117714
[No Abstract] [Full Text] [Related]
33. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes following en bloc resection for pancreatic ductal adenocarcinoma of the head with portomesenteric venous invasion.
Han S; Choi DW; Choi SH; Heo JS; Han IW; You YH
Asian J Surg; 2021 Jan; 44(1):313-320. PubMed ID: 32972828
[TBL] [Abstract][Full Text] [Related]
35. MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer.
Bae JS; Kim JH; Joo I; Chang W; Han JK
Eur Radiol; 2019 Jul; 29(7):3714-3724. PubMed ID: 30899975
[TBL] [Abstract][Full Text] [Related]
36. Borderline resectable pancreatic cancer.
Hackert T; Ulrich A; Büchler MW
Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
[TBL] [Abstract][Full Text] [Related]
37. Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions.
Pine JK; Haugk B; Robinson SM; Darne A; Wilson C; Sen G; French JJ; White SA; Manas DM; Charnley RM
Pancreatology; 2020 Apr; 20(3):537-544. PubMed ID: 31996296
[TBL] [Abstract][Full Text] [Related]
38. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
39. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis.
Yoon MS; Lee HS; Kang CM; Lee WJ; Keum J; Sung MJ; Kim SS; Park MS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Hwang HK; Bang S
Gut Liver; 2022 Jan; 16(1):118-128. PubMed ID: 34140428
[TBL] [Abstract][Full Text] [Related]
40. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
Kim HY; Lee YJ; Chang W; Cho J; Park JH; Lee JC; Kim J; Hwang JH; Kim YH
Eur Radiol; 2022 Jun; 32(6):3799-3807. PubMed ID: 35032213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
